Cellular replacement therapy for Parkinson's disease--where we are today?
about
AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons.Cell-based therapies for Parkinson's disease: past, present, and futureEmbryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNFCell based therapies in Parkinson's Disease.Large animal models are critical for rationally advancing regenerative therapiesCellular repair in the parkinsonian nonhuman primate brain.Nonhuman primate models of Parkinson's disease.In vivo monitoring of cellular transplants by magnetic resonance imaging and positron emission tomography.Cell transplantation for Parkinson's disease.Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells.Cellular transplantation strategies for spinal cord injury and translational neurobiologyThinking about the human neuron mouse.Melatonin-based therapeutics for neuroprotection in stroke.Stem cells in development of therapeutics for Parkinson's disease: a perspectiveComparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinson's Disease.Melatonin as an Antioxidant for Stroke Neuroprotection.The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease.The enhancement of neural stem cell survival and growth by coculturing with expanded Sertoli cells in vitro.The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: Protein distribution and the glial response.Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons.Primate adult brain cell autotransplantation, a pilot study in asymptomatic MPTP-treated monkeys.Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis.Mannitol facilitates neurotrophic factor up-regulation and behavioural recovery in neonatal hypoxic-ischaemic rats with human umbilical cord blood grafts.The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.Primate adult brain cell autotransplantation produces behavioral and biological recovery in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian St. Kitts monkeys.Using monkeys to understand and cure Parkinson disease.Cytometric catheter for neurosurgical applications.Between truth and hope: on Parkinson’s disease, neurotransplantation and the production of the ‘self’
P2860
Q33791830-ECE31129-DDC7-4CF2-A53A-0AAABA2A06C0Q33818127-E96FD2E7-AAA4-4FC2-8C74-BA534C2D8DBEQ33897505-B93E1285-AAA7-4D02-96C7-1E06E16FBE19Q33979529-40A86851-7ADB-44E5-A8D8-54E1A0913DC6Q33999256-F1A3D220-B7C5-4803-AF3B-963BAD8727AAQ34157142-01111701-1640-46CA-9392-B48033711A79Q34665820-1445B3E5-89B9-4D85-BFC6-D94C3B992241Q35681494-07013FDB-E962-48F6-A070-49266BBA961DQ35806033-3D6CD0F4-1EAA-424F-B628-C21DFBD362FEQ35850739-49C15532-FFDA-4F2C-8DDC-8FEDCBB1D8FCQ36045383-E1629EC5-8CA2-4FAA-A426-FEB9E7C913BDQ36417482-396242D7-5504-4983-8CBB-045BBC25A48CQ36913537-7145B828-9EDF-43E4-BDDE-0332D9667FA0Q37002530-1E987718-4BA6-4B80-9DAF-3B749BC06944Q37393795-B2619EDD-2F52-4C67-8C78-C9CC68EF8A0FQ38207680-0832C266-468F-404C-A4C5-352B58D6A41BQ38599709-4C72566C-9681-437A-BFE5-3326674D2A26Q38615563-033F41CC-07F3-43EA-8D08-AB7050921142Q39192172-7C93284D-80E3-445C-A5C0-2D4DCCA9D742Q39438497-51026C17-D328-4AEF-A358-2B979DDB9885Q39604761-8FFB1448-CA99-465F-8B20-997F777D610BQ39817609-4F332CCF-7E14-4BB4-A7EC-1099E43196FDQ39973294-1B803BBF-C153-4F4E-82FF-CC72A77E68B5Q41812779-8A4EB1A4-B8D8-4D01-BC2B-17737463F9C1Q42914219-53966BD2-21AE-4DD7-9C36-DD0CFC7D9E52Q43070160-A3FBB733-7420-4525-BFD6-CDD2A48F5114Q46921956-A98FA20A-D416-47F4-AAEB-9E0F74D79A4FQ48219341-FE4B6954-25D5-4291-9A1C-EEF61E016064Q48270991-3FD00310-3625-42D5-B347-2A9E760647D5Q58188419-A84E33F1-34E8-4264-8B6B-797C22375A5A
P2860
Cellular replacement therapy for Parkinson's disease--where we are today?
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Cellular replacement therapy for Parkinson's disease--where we are today?
@ast
Cellular replacement therapy for Parkinson's disease--where we are today?
@en
Cellular replacement therapy for Parkinson's disease--where we are today?
@nl
type
label
Cellular replacement therapy for Parkinson's disease--where we are today?
@ast
Cellular replacement therapy for Parkinson's disease--where we are today?
@en
Cellular replacement therapy for Parkinson's disease--where we are today?
@nl
altLabel
Book Review: Cellular Replacement Therapy for Parkinson's Disease--Where We Are Today?
@en
prefLabel
Cellular replacement therapy for Parkinson's disease--where we are today?
@ast
Cellular replacement therapy for Parkinson's disease--where we are today?
@en
Cellular replacement therapy for Parkinson's disease--where we are today?
@nl
P2860
P356
P1433
P1476
Book Review: Cellular Replacement Therapy for Parkinson's Disease--Where We Are Today?
@en
Cellular replacement therapy for Parkinson's disease--where we are today?
@en
P2093
D Eugene Redmond
D. E. Redmond
P2860
P356
10.1177/107385802237703
P407
P577
2002-10-01T00:00:00Z